KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Net Margin (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Net Margin readings, the most recent being 37.16% for Q4 2025.

  • On a quarterly basis, Net Margin rose 7923.0% to 37.16% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.04%, a 210.0% decrease, with the full-year FY2025 number at 5.62%, up 995.0% from a year prior.
  • Net Margin hit 37.16% in Q4 2025 for Esperion Therapeutics, up from 36.66% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 42.29% in Q1 2024 to a low of 1140.0% in Q1 2021.
  • Median Net Margin over the past 5 years was 151.63% (2023), compared with a mean of 217.35%.
  • Biggest five-year swings in Net Margin: soared 313267bps in 2021 and later plummeted -24628bps in 2022.
  • Esperion Therapeutics' Net Margin stood at 448.4% in 2021, then skyrocketed by 33bps to 302.06% in 2022, then soared by 41bps to 178.06% in 2023, then soared by 76bps to 42.07% in 2024, then soared by 188bps to 37.16% in 2025.
  • The last three reported values for Net Margin were 37.16% (Q4 2025), 36.66% (Q3 2025), and 16.25% (Q2 2025) per Business Quant data.